progressive multifocal leukoencephalopathy pml rare often fatal viral disease characterized progressive damage pathy inflammation white matter leuko brain encephalo multiple locations multifocal caused jc virus normally present kept control immune system jc virus harmless except cases weakened immune systems general pml mortality rate first months survive left varying degrees neurological disabilities pml occurs almost exclusively patients severe immune deficiency commonly among patients acquired immune deficiency syndrome aids people chronic immunosuppressive medications including chemotherapy also increased risk pml patients transplants hodgkins lymphoma multiple sclerosis psoriasis rheumatoid arthritis autoimmune diseases symptoms develop several weeks months depend location damage brain degree damage prominent symptoms clumsiness progressive weakness visual speech sometimes personality lesions affecting parietal occipital lobes brain lead phenomenon known alien hand cause pml type polyomavirus called jc virus jcv initials person john cunningham whose tissue virus first successfully cultured publications indicate general population seropositive antibodies jcv indicating current previous infection virus publications put percentage general jcv causes persistent asymptomatic infection onethird adult population based viral shedding urine site asymptomatic infection kidney virus causes disease immune system severely pml common people infection prior advent effective antiretroviral therapy many people aids eventually developed pml occurs frequently people aids immunosuppressive conditions unclear research suggests effects hiv brain tissue jcv make jcv likely become active brain increase damaging inflammatory pml still occur people immunosuppressive therapy efalizumab belatacept various transplant drugs meant weaken immune natalizumab tysabri approved fda treatment multiple sclerosis ms supposedly works preventing white blood cells entering brain subsequently withdrawn market manufacturer linked three cases three initial cases taking natalizumab combination interferon safety review drug returned market monotherapy ms special prescription may cases pml reported ms patients patients taken natalizumab none taken drug combination diseasemodifying treatments previous use ms treatments increases risk pml three estimated prevalence pml ms cases per thousand natalizumab around ms patients pml die rest one case study describes ms patient course dimethyl fumarate developed pml fingolimod gilenya approved fda ms first case pml case probable pml reported two gilenya users could tied previous immunosuppressant therapies new cases added drug information sheet included every prescription ie drug pml demyelinating disease myelin sheath covering axons nerve cells gradually destroyed impairing transmission nerve impulses affects subcortical white matter particularly parietal occipital lobes pml destroys oligodendrocytes produces intranuclear inclusions similar another demyelinating disease ms progresses much quickly breakdown myelin proportional degree pml diagnosed patient progressive course disease finding jc virus dna spinal fluid together consistent whitematter lesions brain magnetic resonance imaging mri alternatively brain biopsy typical histopathology demyelination bizarre astrocytes enlarged oligodendroglial nuclei present coupled techniques showing presence jc characteristic evidence pml brain ct scan images multifocal noncontrast enhancing hypodense lesions without mass effect mri far sensitive common area involvement cortical white matter frontal parieto occipital lobes lesions may occur anywhere brain basal ganglia external capsule posterior cranial fossa structures brain stem although typically multifocal natalizumabassociated pml often monofocal predominantly frontal drugs effectively inhibit cure virus infection without toxicity therefore treatment aims reversing immune deficiency slow stop disease progress patients immunosuppression means stopping drugs using plasma exchange accelerate removal biologic agent put person risk hivinfected people may mean starting highly active antiretroviral therapy haart aids patients starting haart diagnosed pml tend slightly longer survival time patients already haart develop aids patients pml able survive several years rare complication effective haart immune reconstitution inflammatory syndrome iris increased immune system activity actually increases damage caused jcv infection although iris often managed medication extremely dangerous cidofovir studied possible treatment used casebycase basis working others cytarabine also known arac chemotherapy drug used treat certain cancers prescribed experimental basis small number nonaids pml patients stabilized neurological condition minority one patient regained cognitive function lost result june first case report appeared pml patient successfully treated antimalarial drug mefloquine activity jc virus patient cleared virus neurological two case reports using successfully success reported mirtazapine demonstrated clinical number drugs work jc virus cell culture proven effective therapy known example suppresses found toxicity therapeutic infusion donor cells specific related bk polyomavirus shown possible effect treating pml one small study katy rezvanis group needs december cellevolve announced launching clinical trial treatment pml utilizing bk virus specific tcells onethird onehalf people pml die first months following diagnosis depending severity underlying disease survivors left variable degrees neurological disease httpsenwikipediaorgwikiprogressivemultifocalleukoencephalopathy